As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to public health through the prevention of influenza and pandemic preparedness. With state-of-the-art production facilities and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

In Australia, CSL Seqirus operates the only manufacturing facility for seasonal and pandemic influenza vaccines, and produces a range of unique medicines in the national interest including antivenoms and the only human vaccine for Q fever. Our commitment to Australia’s health also extends to providing access to paediatric and adult vaccines, and innovative pharmaceuticals for patients living with allergies, cardiovascular disease, severe pain, dry eye disease, iron deficiency, kidney diseases, rare diseases and neurological conditions.